Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DT-CAR-NK
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DT-CAR-NK is an allogeneic, dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech for the treatment of advanced or metastatic breast cancer. The therapy is designed to be biomarker-guided, where patients are treated with a specific dual-target CAR-NK product tailored to their tumor's antigen profile. The primary targets include Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2), Mucin 1 (MUC1), and Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), with Mesothelin (MSLN) also considered for certain triple-negative breast cancer (TNBC) cases. By utilizing NK cells rather than T cells, the therapy aims to provide an 'off-the-shelf' allogeneic option with a potentially lower risk of graft-versus-host disease (GvHD). The treatment protocol typically involves a short course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide prior to intravenous infusion of the CAR-NK cells to optimize cell persistence and anti-tumor activity.
- Other names
- Dual-target CAR-NK cellsAllogeneic dual-target CAR-NK cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)MUC1 (Mucin-1 Antigen)MesothelinROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on EB-DT-CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DT-CAR-NK.